Selected research
Market Structure
Global Uric Acid-lowering Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Uric Acid-lowering Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Uric Acid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Uric Acid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Uric Acid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Uric Acid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Uric Acid-lowering Drugs include Takeda Pharmaceuticals, Teva, Sanwa Kagaku Kenkyusho, Sanofi, GSK, AstraZeneca, Towa Pharmaceutical, Toa Eiyo and Mylan Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Uric Acid-lowering Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Uric Acid-lowering Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Uric Acid-lowering Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Uric Acid-lowering Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Uric Acid-lowering Drugs Segment by Company
Takeda Pharmaceuticals
Teva
Sanwa Kagaku Kenkyusho
Sanofi
GSK
AstraZeneca
Towa Pharmaceutical
Toa Eiyo
Mylan Pharmaceuticals
Mochida Pharmaceutical
Lannett Company
Horizon Therapeutics
Fuji Yakuhin
Uric Acid-lowering Drugs Segment by Type
Uric Acid Production Inhibitors
Uric Acid Dissolving Agents
Urate-stimulating Excretion Agents
Uric Acid-lowering Drugs Segment by Application
Hyperuricemia
Uric Acid Kidney Stones
Gout
Other
Uric Acid-lowering Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uric Acid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Uric Acid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uric Acid-lowering Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Uric Acid-lowering Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Uric Acid-lowering Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Uric Acid-lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Uric Acid-lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Uric Acid Production Inhibitors
- Uric Acid Dissolving Agents
- Urate-stimulating Excretion Agents
Applications
- Hyperuricemia
- Uric Acid Kidney Stones
- Gout
- Other
Companies covered
- Takeda Pharmaceuticals
- Teva
- Sanwa Kagaku Kenkyusho
- Sanofi
- GSK
- AstraZeneca
- Towa Pharmaceutical
- Toa Eiyo
- Mylan Pharmaceuticals
- Mochida Pharmaceutical
- Lannett Company
- Horizon Therapeutics
- Fuji Yakuhin
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Uric Acid-lowering Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Uric Acid-lowering Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Uric Acid-lowering Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Uric Acid-lowering Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Uric Acid-lowering Drugs Market Dynamics
- 2.1 Uric Acid-lowering Drugs Industry Trends
- 2.2 Uric Acid-lowering Drugs Industry Drivers
- 2.3 Uric Acid-lowering Drugs Industry Opportunities and Challenges
- 2.4 Uric Acid-lowering Drugs Industry Restraints
3 Uric Acid-lowering Drugs Market by Manufacturers
- 3.1 Global Uric Acid-lowering Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Uric Acid-lowering Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Uric Acid-lowering Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Uric Acid-lowering Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Uric Acid-lowering Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Uric Acid-lowering Drugs Manufacturers, Product Type & Application
- 3.7 Global Uric Acid-lowering Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Uric Acid-lowering Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Uric Acid-lowering Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Uric Acid-lowering Drugs Tier 1, Tier 2, and Tier 3
4 Uric Acid-lowering Drugs Market by Type
- 4.1 Uric Acid-lowering Drugs Type Introduction
- 4.1.1 Uric Acid Production Inhibitors
- 4.1.2 Uric Acid Dissolving Agents
- 4.1.3 Urate-stimulating Excretion Agents
- 4.2 Global Uric Acid-lowering Drugs Sales by Type
- 4.2.1 Global Uric Acid-lowering Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Uric Acid-lowering Drugs Sales by Type (2021-2032)
- 4.2.3 Global Uric Acid-lowering Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Uric Acid-lowering Drugs Revenue by Type
- 4.3.1 Global Uric Acid-lowering Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Uric Acid-lowering Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Uric Acid-lowering Drugs Revenue Market Share by Type (2021-2032)
5 Uric Acid-lowering Drugs Market by Application
- 5.1 Uric Acid-lowering Drugs Application Introduction
- 5.1.1 Hyperuricemia
- 5.1.2 Uric Acid Kidney Stones
- 5.1.3 Gout
- 5.1.4 Other
- 5.2 Global Uric Acid-lowering Drugs Sales by Application
- 5.2.1 Global Uric Acid-lowering Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Uric Acid-lowering Drugs Sales by Application (2021-2032)
- 5.2.3 Global Uric Acid-lowering Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Uric Acid-lowering Drugs Revenue by Application
- 5.3.1 Global Uric Acid-lowering Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Uric Acid-lowering Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Uric Acid-lowering Drugs Revenue Market Share by Application (2021-2032)
6 Global Uric Acid-lowering Drugs Sales by Region
- 6.1 Global Uric Acid-lowering Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Uric Acid-lowering Drugs Sales by Region (2021-2032)
- 6.2.1 Global Uric Acid-lowering Drugs Sales by Region (2021-2026)
- 6.2.2 Global Uric Acid-lowering Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Uric Acid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Uric Acid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Uric Acid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Uric Acid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Uric Acid-lowering Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Uric Acid-lowering Drugs Revenue by Region
- 7.1 Global Uric Acid-lowering Drugs Revenue by Region
- 7.1.1 Global Uric Acid-lowering Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Uric Acid-lowering Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Uric Acid-lowering Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Uric Acid-lowering Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Uric Acid-lowering Drugs Revenue (2021-2032)
- 7.2.2 North America Uric Acid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Uric Acid-lowering Drugs Revenue (2021-2032)
- 7.3.2 Europe Uric Acid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Uric Acid-lowering Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Uric Acid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Uric Acid-lowering Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Uric Acid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Takeda Pharmaceuticals
- 8.1.1 Takeda Pharmaceuticals Company Information
- 8.1.2 Takeda Pharmaceuticals Business Overview
- 8.1.3 Takeda Pharmaceuticals Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
- 8.1.5 Takeda Pharmaceuticals Recent Developments
- 8.2 Teva
- 8.2.1 Teva Company Information
- 8.2.2 Teva Business Overview
- 8.2.3 Teva Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Teva Uric Acid-lowering Drugs Product Portfolio
- 8.2.5 Teva Recent Developments
- 8.3 Sanwa Kagaku Kenkyusho
- 8.3.1 Sanwa Kagaku Kenkyusho Company Information
- 8.3.2 Sanwa Kagaku Kenkyusho Business Overview
- 8.3.3 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Product Portfolio
- 8.3.5 Sanwa Kagaku Kenkyusho Recent Developments
- 8.4 Sanofi
- 8.4.1 Sanofi Company Information
- 8.4.2 Sanofi Business Overview
- 8.4.3 Sanofi Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sanofi Uric Acid-lowering Drugs Product Portfolio
- 8.4.5 Sanofi Recent Developments
- 8.5 GSK
- 8.5.1 GSK Company Information
- 8.5.2 GSK Business Overview
- 8.5.3 GSK Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 GSK Uric Acid-lowering Drugs Product Portfolio
- 8.5.5 GSK Recent Developments
- 8.6 AstraZeneca
- 8.6.1 AstraZeneca Company Information
- 8.6.2 AstraZeneca Business Overview
- 8.6.3 AstraZeneca Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 AstraZeneca Uric Acid-lowering Drugs Product Portfolio
- 8.6.5 AstraZeneca Recent Developments
- 8.7 Towa Pharmaceutical
- 8.7.1 Towa Pharmaceutical Company Information
- 8.7.2 Towa Pharmaceutical Business Overview
- 8.7.3 Towa Pharmaceutical Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Towa Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
- 8.7.5 Towa Pharmaceutical Recent Developments
- 8.8 Toa Eiyo
- 8.8.1 Toa Eiyo Company Information
- 8.8.2 Toa Eiyo Business Overview
- 8.8.3 Toa Eiyo Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Toa Eiyo Uric Acid-lowering Drugs Product Portfolio
- 8.8.5 Toa Eiyo Recent Developments
- 8.9 Mylan Pharmaceuticals
- 8.9.1 Mylan Pharmaceuticals Company Information
- 8.9.2 Mylan Pharmaceuticals Business Overview
- 8.9.3 Mylan Pharmaceuticals Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Mylan Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
- 8.9.5 Mylan Pharmaceuticals Recent Developments
- 8.10 Mochida Pharmaceutical
- 8.10.1 Mochida Pharmaceutical Company Information
- 8.10.2 Mochida Pharmaceutical Business Overview
- 8.10.3 Mochida Pharmaceutical Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Mochida Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
- 8.10.5 Mochida Pharmaceutical Recent Developments
- 8.11 Lannett Company
- 8.11.1 Lannett Company Company Information
- 8.11.2 Lannett Company Business Overview
- 8.11.3 Lannett Company Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Lannett Company Uric Acid-lowering Drugs Product Portfolio
- 8.11.5 Lannett Company Recent Developments
- 8.12 Horizon Therapeutics
- 8.12.1 Horizon Therapeutics Company Information
- 8.12.2 Horizon Therapeutics Business Overview
- 8.12.3 Horizon Therapeutics Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Horizon Therapeutics Uric Acid-lowering Drugs Product Portfolio
- 8.12.5 Horizon Therapeutics Recent Developments
- 8.13 Fuji Yakuhin
- 8.13.1 Fuji Yakuhin Company Information
- 8.13.2 Fuji Yakuhin Business Overview
- 8.13.3 Fuji Yakuhin Uric Acid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Fuji Yakuhin Uric Acid-lowering Drugs Product Portfolio
- 8.13.5 Fuji Yakuhin Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Uric Acid-lowering Drugs Value Chain Analysis
- 9.1.1 Uric Acid-lowering Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Uric Acid-lowering Drugs Production Mode & Process
- 9.2 Uric Acid-lowering Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Uric Acid-lowering Drugs Distributors
- 9.2.3 Uric Acid-lowering Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst